loading
Cartesian Therapeutics Inc stock is traded at $13.34, with a volume of 12,055. It is down -1.56% in the last 24 hours and up +23.14% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
See More
Previous Close:
$13.46
Open:
$13.46
24h Volume:
12,055
Relative Volume:
0.17
Market Cap:
$343.38M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.2679
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
+11.91%
1M Performance:
+23.14%
6M Performance:
-30.99%
1Y Performance:
-20.08%
1-Day Range:
Value
$12.56
$13.46
1-Week Range:
Value
$11.80
$13.81
52-Week Range:
Value
$8.46
$26.50

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name
Name
Cartesian Therapeutics Inc
Name
Phone
301-348-8698
Name
Address
7495 NEW HORIZON WAY, FREDERICK
Name
Employee
66
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
RNAC's Discussions on Twitter

Compare RNAC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RNAC
Cartesian Therapeutics Inc
13.23 347.53M 26.00M -219.71M -51.37M -49.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
467.57 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.70 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.74 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.96 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
292.44 31.91B 3.81B -644.79M -669.77M -6.24

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-09-25 Initiated Wedbush Outperform
Dec-19-24 Initiated BTIG Research Buy
Aug-06-24 Initiated TD Cowen Buy
Jul-02-24 Downgrade Oppenheimer Outperform → Perform
Jun-04-24 Initiated Oppenheimer Outperform
May-24-24 Initiated Mizuho Buy
Apr-23-24 Reiterated H.C. Wainwright Buy
Apr-23-24 Initiated Leerink Partners Outperform
Aug-18-23 Downgrade SVB Securities Outperform → Market Perform
Jun-14-22 Reiterated Needham Buy
Jun-06-22 Initiated SVB Leerink Outperform
Jun-15-21 Initiated BTIG Research Buy
Jan-26-21 Upgrade Mizuho Neutral → Buy
Oct-01-20 Downgrade Mizuho Buy → Neutral
Oct-01-20 Downgrade William Blair Outperform → Mkt Perform
Jun-12-20 Downgrade Stifel Buy → Hold
Apr-28-20 Initiated H.C. Wainwright Buy
Jan-29-20 Initiated Cantor Fitzgerald Overweight
Jan-21-20 Initiated William Blair Outperform
Jun-27-18 Initiated Janney Buy
Mar-30-17 Reiterated UBS Buy
View All

Cartesian Therapeutics Inc Stock (RNAC) Latest News

pulisher
05:40 AM

What drives Cartesian Therapeutics Inc. stock priceOutstanding trading profits - PrintWeekIndia

05:40 AM
pulisher
01:05 AM

Is Cartesian Therapeutics Inc. stock a good hedge against inflationSuperior risk-adjusted returns - jammulinksnews.com

01:05 AM
pulisher
12:39 PM

When is the best time to buy Cartesian Therapeutics Inc. stockBreakthrough capital growth - jammulinksnews.com

12:39 PM
pulisher
Jul 24, 2025

Is Cartesian Therapeutics Inc. a good long term investmentHigh-profit stock alerts - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate - Benzinga

Jul 24, 2025
pulisher
Jul 24, 2025

Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last? - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Cartesian Therapeutics Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Cartesian Therapeutics Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What makes Cartesian Therapeutics Inc. stock price move sharplyFree Stock Market Swing Trading Strategies - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics - MenaFN

Jul 22, 2025
pulisher
Jul 15, 2025

Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionCarefully Curated High Return Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Cartesian Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $40.00 Average Price Target from Analysts - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

What is Wedbush’s Estimate for RNAC Q2 Earnings? - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Wedbush Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

CartesianAutoimmune Cell Therapy Excites, But Reality Bites (NASDAQ:RNAC) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Wedbush Initiates Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $38 - 富途牛牛

Jul 10, 2025
pulisher
Jul 09, 2025

Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating - Investing.com Canada

Jul 09, 2025
pulisher
Jul 09, 2025

Cartesian stock up as Wedbush becomes bullish (RNAC:NASDAQ) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Cartesian Therapeutics' 15min chart sees KDJ Golden Cross, bullish Marubozu formation. - AInvest

Jul 09, 2025
pulisher
Jun 30, 2025

AbbVie Makes Big Autoimmune CAR-T Play With Capstan Acquisition - insights.citeline.com

Jun 30, 2025
pulisher
Jun 28, 2025

What caused RNAC's earnings to miss forecasts in Q4 2023? - AInvest

Jun 28, 2025
pulisher
Jun 26, 2025

Rhumbline Advisers Grows Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jun 26, 2025
pulisher
Jun 21, 2025

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance

Jun 21, 2025
pulisher
Jun 18, 2025

Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - The Globe and Mail

Jun 18, 2025
pulisher
Jun 18, 2025

IBM Introduces Industry-First Software to Unify Agentic Governance and Security - The Globe and Mail

Jun 18, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics holds annual stockholders meeting By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics holds annual stockholders meeting - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by Bank of America Corp DE - Defense World

Jun 16, 2025

Cartesian Therapeutics Inc Stock (RNAC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Cartesian Therapeutics Inc Stock (RNAC) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
English Emily
Chief Operations Officer
Apr 15 '25
Option Exercise
3.30
7,500
24,750
47,726
SPRINGER TIMOTHY A
Director
Apr 10 '25
Buy
10.47
48,595
508,751
620,175
SPRINGER TIMOTHY A
Director
Apr 09 '25
Buy
9.43
41,782
393,947
571,580
SPRINGER TIMOTHY A
Director
Apr 11 '25
Buy
10.77
36,338
391,455
656,513
SPRINGER TIMOTHY A
Director
Apr 10 '25
Buy
10.47
8,575
89,773
8,637,273
SPRINGER TIMOTHY A
Director
Apr 09 '25
Buy
9.43
7,373
69,517
8,628,698
SPRINGER TIMOTHY A
Director
Apr 11 '25
Buy
10.77
6,412
69,074
8,643,685
SPRINGER TIMOTHY A
Director
Mar 20 '25
Buy
15.59
54,889
855,593
8,621,325
SPRINGER TIMOTHY A
Director
Mar 19 '25
Buy
14.97
20,234
302,962
8,566,436
SPRINGER TIMOTHY A
Director
Mar 18 '25
Buy
14.42
14,740
212,599
8,546,202
$23.29
price down icon 1.74%
$36.50
price up icon 0.00%
$103.56
price down icon 0.03%
$27.38
price down icon 0.69%
$113.86
price down icon 0.68%
biotechnology ONC
$288.37
price down icon 2.39%
Cap:     |  Volume (24h):